Materials and methods for altering an immune response to exogenous and endogenous immunogens, including syngeneic and non-syngeneic cells, tissues or organs

Details for Australian Patent Application No. 2006238892 (hide)

Owner Massachusetts Institute of Technology Pervasis Therapeutics, Inc.

Inventors Edelman, Elazer R.; Nugent, Helen Marie; Methe, Heiko

Agent Griffith Hack

Pub. Number AU-B-2006238892

PCT Pub. Number WO2006/116357

Priority 60/673,417 21.04.05 US; 60/682,217 18.05.05 US

Filing date 21 April 2006

Wipo publication date 2 November 2006

Acceptance publication date 27 January 2011

International Classifications

C12N 5/071 (2010.01) Undifferentiated human, animal or plant cells, e.g. cell lines - Vertebrate cells or tissues, e.g. human cells or tissues

A61K 35/12 (2006.01) Medicinal preparations containing material or reaction products thereof with undetermined constitution - Materials from mammals or birds

Event Publications

6 December 2007 PCT application entered the National Phase

  PCT publication WO2006/116357 Priority application(s): WO2006/116357

27 January 2011 Application Accepted

  Published as AU-B-2006238892

26 May 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006238895-Evaluating bacterial lethality of containerized food production

2006238888-N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress